Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

The Importance of a Novel Syndemic Approach for Cardiometabolic Diseases

Author(s): Manfredi Rizzo*

Volume 31, Issue 18, 2024

Published on: 25 September, 2023

Page: [2483 - 2485] Pages: 3

DOI: 10.2174/0929867331666230918114009

Next »
[1]
Rizvi, A.A.; Kathuria, A.; Al Mahmeed, W.; Al-Rasadi, K.; Al-Alawi, K.; Banach, M.; Banerjee, Y.; Ceriello, A.; Cesur, M.; Cosentino, F.; Galia, M.; Goh, S.Y.; Janez, A.; Kalra, S.; Kempler, P.; Lessan, N.; Lotufo, P.; Papanas, N.; Santos, R.D.; Stoian, A.P.; Toth, P.P.; Viswanathan, V.; Rizzo, M. Post-COVID syndrome, inflammation, and diabetes. J. Diabetes Complications, 2022, 36(11), 108336.
[http://dx.doi.org/10.1016/j.jdiacomp.2022.108336] [PMID: 36228563]
[2]
Kapoor, N.; Kalra, S.; Al Mahmeed, W.; Al-Rasadi, K.; Al-Alawi, K.; Banach, M.; Banerjee, Y.; Ceriello, A.; Cesur, M.; Cosentino, F.; Firenze, A.; Galia, M.; Goh, S.Y.; Janez, A.; Kempler, P.; Lessan, N.; Lotufo, P.; Papanas, N.; Rizvi, A.A.; Sahebkar, A.; Santos, R.D.; Stoian, A.P.; Toth, P.P.; Viswanathan, V.; Rizzo, M. The dual pandemics of COVID-19 and obesity: Bidirectional impact. Diabetes Ther., 2022, 13(10), 1723-1736.
[http://dx.doi.org/10.1007/s13300-022-01311-2] [PMID: 36030317]
[3]
Al Mahmeed, W.; Al-Rasadi, K.; Banerjee, Y.; Ceriello, A.; Cosentino, F.; Galia, M.; Goh, S.Y.; Kempler, P.; Lessan, N.; Papanas, N.; Rizvi, A.A.; Santos, R.D.; Stoian, A.P.; Toth, P.P.; Rizzo, M. Promoting a syndemic approach for cardiometabolic disease management during COVID-19: The CAPISCO international expert panel. Front. Cardiovasc. Med., 2021, 8, 787761.
[http://dx.doi.org/10.3389/fcvm.2021.787761] [PMID: 34977193]
[4]
Rizzo, M.; Foresti, L.; Montano, N. Comparison of reported deaths from COVID-19 and increase in total mortality in Italy. JAMA Intern. Med., 2020, 180(9), 1250-1252.
[http://dx.doi.org/10.1001/jamainternmed.2020.2543] [PMID: 32702088]
[5]
Powell-Wiley, T.M. Centering patient voices through community engagement in cardiovascular research. Circulation, 2023, 147(2), 105-107.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.122.061112] [PMID: 36622908]
[6]
Lo Presti, E.; Nuzzo, D.; Al Mahmeed, W.; Al-Rasadi, K.; Al-Alawi, K.; Banach, M.; Banerjee, Y.; Ceriello, A.; Cesur, M.; Cosentino, F.; Firenze, A.; Galia, M.; Goh, S.Y.; Janez, A.; Kalra, S.; Kapoor, N.; Kempler, P.; Lessan, N.; Lotufo, P.; Papanas, N.; Rizvi, A.A.; Sahebkar, A.; Santos, R.D.; Stoian, A.P.; Toth, P.P.; Viswanathan, V.; Rizzo, M. Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health. Biochim. Biophys. Acta Mol. Basis Dis., 2022, 1868(12), 166559.
[http://dx.doi.org/10.1016/j.bbadis.2022.166559] [PMID: 36174875]
[7]
Popovic, D.S.; Papanas, N.; Pantea Stoian, A.; Rizvi, A.A.; Janez, A.; Rizzo, M. Use of novel antidiabetic agents in patients with type 2 diabetes and COVID-19: A critical review. Diabetes Ther., 2021, 12(12), 3037-3054.
[http://dx.doi.org/10.1007/s13300-021-01170-3] [PMID: 34699021]
[8]
Han, T.; Ma, S.; Sun, C.; Zhang, H.; Qu, G.; Chen, Y.; Cheng, C.; Chen, E.L.; Ayaz Ahmed, M.; Kim, K.Y.; Manem, R.; Chen, M.; Guo, Z.; Yang, H.; Yan, Y.; Zhou, Q. The association between anti-diabetic agents and clinical outcomes of COVID-19 in patients with diabetes: A systematic review and meta-analysis. Arch. Med. Res., 2021, 21, S0188-S4409.
[9]
Kosiborod, M.N.; Esterline, R.; Furtado, R.H.M.; Oscarsson, J.; Gasparyan, S.B.; Koch, G.G.; Martinez, F.; Mukhtar, O.; Verma, S.; Chopra, V.; Buenconsejo, J.; Langkilde, A.M.; Ambery, P.; Tang, F.; Gosch, K.; Windsor, S.L.; Akin, E.E.; Soares, R.V.P.; Moia, D.D.F.; Aboudara, M.; Hoffmann Filho, C.R.; Feitosa, A.D.M.; Fonseca, A.; Garla, V.; Gordon, R.A.; Javaheri, A.; Jaeger, C.P.; Leaes, P.E.; Nassif, M.; Pursley, M.; Silveira, F.S.; Barroso, W.K.S.; Lazcano Soto, J.R.; Nigro Maia, L.; Berwanger, O. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol., 2021, 9(9), 586-594.
[http://dx.doi.org/10.1016/S2213-8587(21)00180-7] [PMID: 34302745]
[10]
Rizzo, M.; Nauck, M.A.; Mantzoros, C.S. Incretin-based therapies in 2021 – Current status and perspectives for the future. Metabolism, 2021, 122, 154843.
[http://dx.doi.org/10.1016/j.metabol.2021.154843] [PMID: 34333000]
[11]
Ferrannini, G.; Lund, L.H.; Benson, L.; Rizzo, M.; Almahmeed, W.; Rosano, G.M.C.; Savarese, G.; Cosentino, F. Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis. Eur. Heart J. Cardiovasc. Pharmacother., 2022, 9(1), 10-17.
[http://dx.doi.org/10.1093/ehjcvp/pvac044] [PMID: 35963647]
[12]
Banerjee, Y.; Pantea Stoian, A.; Silva-Nunes, J.; Sonmez, A.; Rizvi, A.A.; Janez, A.; Rizzo, M. The role of GLP-1 receptor agonists during COVID-19 pandemia: A hypothetical molecular mechanism. Expert Opin. Drug Saf., 2021, 20(11), 1309-1315.
[http://dx.doi.org/10.1080/14740338.2021.1970744] [PMID: 34424130]
[13]
Rizvi, A.A.; Janez, A.; Rizzo, M. Cardiometabolic alterations in the interplay of COVID-19 and diabetes: Current knowledge and future avenues. Int. J. Mol. Sci., 2021, 22(22), 12311.
[http://dx.doi.org/10.3390/ijms222212311] [PMID: 34830193]
[14]
Pantea Stoian, A.; Pricop-Jeckstadt, M.; Pana, A.; Ileanu, B.V.; Schitea, R.; Geanta, M.; Catrinoiu, D.; Suceveanu, A.I.; Serafinceanu, C.; Pituru, S.; Poiana, C.; Timar, B.; Nitipir, C.; Parvu, S.; Arsene, A.; Mazilu, L.; Toma, A.; Hainarosie, R.; Ceriello, A.; Rizzo, M.; Jinga, V. Death by SARS-CoV 2: A Romanian COVID-19 multi-centre comorbidity study. Sci. Rep., 2020, 10(1), 21613.
[http://dx.doi.org/10.1038/s41598-020-78575-w] [PMID: 33303885]
[15]
Popovic, D.S.; Papanas, N.; Koufakis, T.; Kotsa, K.; Mahmeed, W.A.; Al-Rasadi, K.; Al-Alawi, K.; Banach, M.; Banerjee, Y.; Ceriello, A.; Cesur, M.; Cosentino, F.; Firenze, A.; Galia, M.; Goh, S.Y.; Janez, A.; Kalra, S.; Kempler, P.; Kapoor, N.; Lessan, N.; Lotufo, P.; Rizvi, A.A.; Sahebkar, A.; Santos, R.D.; Stoian, A.P.; Toth, P.P.; Viswanathan, V.; Rizzo, M. Glucometabolic perturbations in type 2 diabetes mellitus and coronavirus disease 2019: Causes, consequences, and how to counter them using novel antidiabetic drugs. Exp. Clin. Endocrinol. Diabetes, 2023, 131(5), 260-267.
[http://dx.doi.org/10.1055/a-2019-1111] [PMID: 36693416]

Rights & Permissions Print Cite
Article Metrics
10
2
© 2024 Bentham Science Publishers | Privacy Policy